Michael D. Jain

7.5k citations

105 papers · 1.5k indexed · 1 hit paper · h-index 22

Impact in

Oncology top 2%
- CAR-T cell therapy research
Pathology and Forensic Medicine top 5%
- Lymphoma Diagnosis and Treatment

Papers in

Oncology 89
- CAR-T cell therapy research 84
Pathology and Forensic Medicine 24
- Lymphoma Diagnosis and Treatment 24

Co-authors: Frederick L. Locke Marco L. Davila Julio C. Chávez Nirali N. Shah Bijal Shah Melody Smith Kai Rejeski Aleksandr Lazaryan
Journals: Blood (31 papers)Transplantation and Cellular Therapy (10 papers)Journal of Clinical Oncology (9 papers)Blood Advances (5 papers)International Journal of Radiation Oncology*Biology*Physics (5 papers)
Partner nations: United States Canada Germany

In The Last Decade

Michael D. Jain

97 papers receiving 1.5k citations

Hit Papers

align trajectories log scale

How I Treat Refractory CRS and ICANS Following CAR T-cell Therapy 2023 · 94 citations

Peers

Countries citing papers authored by Michael D. Jain

Since Specialization

Citations

This map shows the geographic impact of Michael D. Jain's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael D. Jain with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael D. Jain more than expected).

Fields of papers citing papers by Michael D. Jain

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael D. Jain. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael D. Jain. The network helps show where Michael D. Jain may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Michael D. Jain, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Michael D. Jain Line = papers co-authored together Michael D. Jain links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Radiomic features of PET/CT imaging of large B cell lymphoma lesions predicts CAR T cell therapy efficacy Frontiers in Oncology ·Yoganand Balagurunathan, X. Vergara, Jin Qi, Zachary Thompson, Erin Dean, Hong Lü, Saran Vardhanabhuti, E. Le Coarer, Jung Woo Choi, Jenny Kim, Mike Mattie, Michael D. Jain, Frederick L. Locke	2024	2
2	Cohort Comparison of Therapy-Related Myeloid Neoplasms after CAR T-Cell Therapy, Autologous Stem Cell Transplant, and Standard Cancer Therapies Blood ·Juan Manuel Mancilla Díaz, Saurabh Dahiya, Алексей Викторович Самцов, Maeve O’Reilly, Kai Rejeski, Veit Buecklein, Marion Subklewe, Gloria Iacoboni, Pere Barba, Claire Roddie, Frederick L. Locke, Jay Y. Spiegel, Najla H. Al Ali, D. Tonon, Jongphil Kim, Rami S. Komrokji, Michael D. Jain	2024	0
3	Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality Blood Advances ·Kai Rejeski, Yucai Wang, Doris K. Hansen, Gloria Iacoboni, Emmanuel Bachy, Radhika Bansal, Olaf Penack, Fabian Müller, Wolfgang Bethge, Javier Muñoz, Razan Mohty, Veit Bücklein, Pere Barba, Frederick L. Locke, B. Ashtir, Michael D. Jain, Marion Subklewe	2024	29
4	Real-World Patient-Reported and Neurocognitive Outcomes in the Year After Axicabtagene Ciloleucel Transplantation and Cellular Therapy ·Aasha I. Hoogland, Xiaoyin Li, Louis H. Troporcer, Octavio Flores-Calderón, Cai Zhi-hu, Chi Xiaohui, Laura B. Oswald, Julia Thornton Snider, Sally W. Wade, Julio C. Chávez, E. Le Coarer, Margaret Booth‐Jones, Michael D. Jain, Frederick L. Locke, Heather Jim	2024	2
5	Repeatability of metabolic tumor burden and lesion glycolysis between clinical readers Frontiers in Immunology ·Jung Woo Choi, Erin Dean, Hong Lu, Zachary Thompson, Qi Jin, Yoryany Mulato Bolaños, Michael D. Jain, Frederick L. Locke, Yoganand Balagurunathan	2023	5
6	Applying the Novel EHA/EBMT Grading System for Icaht Following CAR-T Therapy: Comparative Incidence across Disease Entities and Association with Infections and Mortality Blood ·Kai Rejeski, Doris K. Hansen, Yucai Wang, Gloria Iacoboni, Emmanuel Bachy, Radhika Bansal, Olaf Penack, S. Karunanidhi, Wolfgang Bethge, Javier Muñoz, Razan Mohty, Veit Buecklein, Pere Barba, Frederick L. Locke, Yi Lin, Michael D. Jain, Marion Subklewe	2023	1
7	The CAR‐HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL American Journal of Hematology ·Kai Rejeski, Yucai Wang, Omar Albanyan, Javier Muñoz, Pierre Sesques, Gloria Iacoboni, Lucía López‐Corral, Al Nyhart, Veit Bücklein, Razan Mohty, Martin Dreyling, Aliyah Baluch, Bijal Shah, Frederick L. Locke, Georg Heß, Pere Barba, Emmanuel Bachy, Yi Lin, Marion Subklewe, Michael D. Jain	2023	17
8	Influence of Adipose Tissue Distribution, Sarcopenia, and Nutritional Status on Clinical Outcomes After CD19 CAR T-cell Therapy Cancer Immunology Research ·Kai Rejeski, David M. Cordas dos Santos, Nathan H. Parker, Veit Bücklein, Michael Winkelmann, Roua Manaa, Qiang Zhao, 陈光祚, Sophie Günther, Philipp Karschnia, Viktoria Blumenberg, Amit Kumar, Wolfgang G. Kunz, Michael von Bergwelt‐Baildon, Michael D. Jain, Sebastian Theurich, Marion Subklewe	2023	20
9	Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11 Clinical Cancer Research ·Michael D. Jain, David B. Miklos, Caron A. Jacobson, John M. Timmerman, J. L. Morrill, Anthony Kelechi Nwangwu, Xiang Fang, Ankit Patel, Madison Davis, Darren Heeke, 剛小林, Mike Mattie, Frank Neumann, Jenny Kim, 陈建秋, Simone Filosto, Ran Reshef	2023	6
10	Circulating tumor DNA adds specificity to PET after axicabtagene ciloleucel in large B-cell lymphoma Blood Advances ·Erin Dean, Chu Chen-ge, Matthew J. Frank, Дмитрий Сергеевич Склезнев, Nasheed Hossain, Michael D. Jain, Saurabh Dahiya, David B. Miklos, Philipp M. Altrock, Frederick L. Locke	2023	16
11	Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphoma Blood ·Michael D. Jain, Bachisio Ziccheddu, Caroline A. Coughlin, Rawan Faramand, Anthony J. Griswold, Kayla Reid, Meghan Menges, Yonghong Zhang, Ling Cen, Xuefeng Wang, Mohammad Hussaini, Ola Landgren, Marco L. Davila, Jonathan H. Schatz, Frederick L. Locke, Francesco Maura	2022	36
12	Patient-Reported Toxicities in Axicabtagene Ciloleucel Recipients: 1-Year Follow-up Transplantation and Cellular Therapy ·Anna Barata, Aasha I. Hoogland, Kelly A. Hyland, Anuhya Kommalapati, Chi Xiaohui, Cai Zhi-hu, Margaret Booth‐Jones, Michael D. Jain, Frederick L. Locke, Heather Jim	2021	1
13	Transverse myelitis after anti‐CD19 directed CAR T cell therapy for relapsed large B cell lymphoma SHILAP Revista de lepidopterología ·Charmi D. Patel, Sepideh Mokhtari, Jeffrey A. Silverman, Kayla Reid, Rawan Faramand, Marco L. Davila, Norman Franke, Frederick L. Locke, Michael D. Jain, Daniel Wong, John Kuruvilla	2021	10
14	Abstract 9828: Active Surveillance of Cardiotoxicity with Cardiac Biomarkers During Chimeric Antigen Receptor T-Cell Therapy Circulation ·Dae Hyun Lee, Sanjay Chandrasekhar, Michael D. Jain, Julio C. Chávez, Bijal Shah, Aleksandr Lazaryan, Farhad Khimani, Taiga Nishihori, Christina A. Bachmeier, Michael G. Fradley, Daniel Jeong, Frederick L. Locke, Guilherme José Pimentel Lopes de Oliveira, Mohammed Alomar	2021	2
15	Monitoring of Circulating Tumor DNA Improves Early Relapse Detection After Axicabtagene Ciloleucel Infusion in Large B-Cell Lymphoma: Results of a Prospective Multi-Institutional Trial Journal of Clinical Oncology ·Matthew J. Frank, Nasheed Hossain, Ali Bukhari, Erin Dean, Jay Y. Spiegel, Gursharan K. Claire, Ilan Kirsch, Allison P. Jacob, Chelsea Mullins, Lik Wee Lee, Katherine A. Kong, Juliana Craig, Crystal L. Mackall, Aaron P. Rapoport, Michael D. Jain, Saurabh Dahiya, Frederick L. Locke, David B. Miklos	2021	87
16	Quality of life in caregivers of patients receiving chimeric antigen receptor T‐cell therapy Psycho-Oncology ·Anna Barata, Aasha I. Hoogland, Kelly A. Hyland, Amy K. Otto, Anuhya Kommalapati, Reena Jayani, Chi Xiaohui, Awadh Mechem A Alokaily, Cai Zhi-hu, Octavio Flores-Calderón, Margaret Booth‐Jones, Jennifer M. Logue, Brent J. Small, Michael D. Jain, Maija Reblin, Frederick L. Locke, Heather Jim	2021	18
17	Factors Affecting Lymphocyte Collection Efficiency and Manufactured Product Specification during Leukapheresis for Diffuse Large B Cell Lymphoma Patients Treated with Commercial Tisagenlecleucel Blood ·Ariel Perez Perez, Christina A. Bachmeier, A. V. Gritsay, Dong Su-xiang, Aleksandr Lazaryan, Julio C. Chávez, Claudio Anasetti, Bijal Shah, Farhad Khimani, Taiga Nishihori, Marco L. Davila, Frederick L. Locke, Michael D. Jain, Hien Liu	2020	3
18	High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma Blood Advances ·Erin Dean, Rahul Mhaskar, Hong Lü, Rashed S. Alharbi, Gabriel Krivenko, Aleksandr Lazaryan, Christina A. Bachmeier, Julio C. Chávez, Taiga Nishihori, Marco L. Davila, Farhad Khimani, Hien Liu, Javier Pinilla‐Ibarz, Bijal Shah, Michael D. Jain, Yoganand Balagurunathan, Frederick L. Locke	2020	146
19	Patterns of Failure Following Chimeric Antigen Receptor T-cell (CAR-T) Therapy International Journal of Radiation OncologyBiologyPhysics ·Nicholas Figura, Michael D. Jain, Austin J. Sim, Julio C. Chávez, Bijal Shah, Farhad Khimani, Aleksandr Lazaryan, A Zaremba, W.J.L.D. Weerasinghe, マックガワンタラ, Timothy J. Robinson	2019	1
20	SubID, a non-median dichotomization tool for heterogeneous populations, reveals the pan-cancer significance of INPP4B and its regulation by EVI1 in AML PLoS ONE ·Irakli Dzneladze, John F. Woolley, Kevin Jeswani, Youqi Han, Ayesha Rashid, Michael D. Jain, Jüri Reimand, Mark D. Minden, Leonardo Salmena	2018	8

About Michael D. Jain

Michael D. Jain is a scholar working on Oncology, Pathology and Forensic Medicine, Immunology, Genetics and Hematology, having authored 105 papers that have together received 1.5k indexed citations. Recurring topics across this work include CAR-T cell therapy research (84 papers), Lymphoma Diagnosis and Treatment (24 papers), Biosimilars and Bioanalytical Methods (12 papers), Virus-based gene therapy research (8 papers), Integrated Circuits and Semiconductor Failure Analysis (8 papers), Chronic Lymphocytic Leukemia Research (7 papers), Cancer Genomics and Diagnostics (7 papers) and Advancements in Semiconductor Devices and Circuit Design (6 papers). The work is most often cited by research in Oncology (1.2k citations), Pathology and Forensic Medicine (320 citations), Genetics (278 citations), Hematology (110 citations) and Immunology (197 citations). Michael D. Jain has collaborated with scholars based in United States, Canada and Germany. Frequent co-authors include Frederick L. Locke, Marco L. Davila, Julio C. Chávez, Nirali N. Shah, Bijal Shah, Melody Smith, Kai Rejeski, Aleksandr Lazaryan, Christina A. Bachmeier and H. A. Risch. Their work appears in journals such as Blood, Transplantation and Cellular Therapy, Journal of Clinical Oncology, Blood Advances and International Journal of Radiation Oncology*Biology*Physics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact